Biomed 2018 – Israeli Life science and technology week 2018-02-19T16:57:10+00:00

About MIXiii-BIOMED 2018

Dear Friends and Colleagues,

It is our honor and pleasure to invite you to participate in the 17th MIXiii-BIOMED 2018 Conference and Exhibition, to be held May 15-17, 2018 in Tel AvivIsrael.

This year we will explore and aim to fuel the innovations and trends that are shaping the future of healthcare systems and life sciences. The conference will be divided into 9 main tracks:

  • Digital Health, IoT, and Big Data – New Armamentarium in Medicine
  • Next Generation Oncology Treatments
  • Brain Health
  • Personalized Diagnostics and Treatments
  • Gene Editing and Therapies
  • Nanomedicine and its Role in New Medical Therapeutics
  • From Academia Research to Industry
  • Cutting Edge Medical Device Technologies: Metabolic, Ophthalmology, Orthopedic
  • Novel Clinical Trial Designs and Technologies to Accelerate Drug Development

As we envision and analyze our projections for the future of healthcare systems, we should address ways to diagnose and treat patients by utilizing next generation methods. With the goal of improving the way we treat, prevent and cure diseases, we should consider innovations in precision and targeted medicine genetics, personal diagnosis, treatment and monitoring.

Read More

When & Where

  • Follow us on:

    color-facebook-128   color-twitter-128   google-plus-circle   color-linkedin-128  

  • Articles related to the field:


INVITED SPEAKERS (Preliminary List)

Arie S. Belldegrun, MD, FACS
Founder & CEO, Kite Pharma

Troy Cox
Chief Executive Officer, Foundation Medicine

Francois Maisonrouge
Senior Managing Director, Evercore Partners

Bruce R. Rosengard, MD
Chief Medical Science and Technology Officer, Johnson & Johnson Medical Devices

Anat Naschitz
Managing Director, Orbimed Advisors

Allen Kamer
Managing Partner, OurCrowd Qure

Prof. David Sidransky, MD
Johns Hopkins School of Medicine and Israel Biotech Fund, Co-Founder and General Partner

Tetsuyuki Maruyama, PhD
Chief Scientific Officer, Dementia Discovery Fund, SV Life Sciences Managers

Iris Grossman, PhD
Former Teva Pharmaceuticals

Prof. Simon Benita, PhD
Head of Nano Delivery Systems, Hebrew University of Jerusalem

Gil Granot-Mayer
CEO, Yeda R&D – Technology Transfer, Weizmann Institute of Science

Irit Yaniv, MD
General Partner, Accelmed

Barak Azmon, MD
Managing Director, Notal Vision

Yael Weiss, MD, PhD
Vice President Business Development, Ultragenyx

Varda Shalev, MD, MPH
Managing Director, Morris Kahn & Maccabi Research and Innovation Institute at Maccabi Health Care Services

Elie Lobel
Chief Executive Officer, Orange Healthcare

Michael L. Salgaller, PhD
Supervisor, Invention Development and Marketing Unit (IDMU), Technology Transfer Center, National Cancer Institute, National Institutes of Health

Prof. Nir Giladi, MD
Director, Neurology Division, Tel Aviv Sourasky Medical Center

Prof. Gideon Rechavi, MD, PhD
Head, Sheba Cancer Research Center

Prof. Dror Harats, MD
Chief Executive Officer, Vascular Biogenics

Shai Rosenberg, MD
Neuro-Oncology and head of Cancer Computational Biology laboratory, Hadassah – Hebrew University Medical Center

Miro Venturi, PhD
Global Head – Diagnostics Biomarkers, F. Hoffmann-La Roche Ltd.

Randy Prebula
Partner, Hogan Lovells, Washington, D.C.

David Fenstermacher, PhD
Vice President R&D-Bioinformatics, Medimmune

David Cassak
Managing Partner, Innovation In Medtech

Daphna Laifenfeld, PhD
Head, Personalized Medicine & diagnostics, Teva Pharmaceuticals

Erhan Bilal, PhD
IBM T.J. Watson Research / Computational Biology Center

Stephen Squinto, PhD
Venture Partner, Orbimed Healthcare Fund Management

Anand Subramony, PhD
Vice President, Novel Product Technologies, MedImmune

Walter Kowtoniuk, PhD
Principle, Third Rock Ventures

Michael Jasulavic
Investment Professional, Investment Advisor, HBM Partners

Tauhid Ali
Vice President and Head of TAK-celerator, Takeda

Felix Frueh, PhD
Executive Partner, Opus Three LLC

Zeev Zehavi
Vice President of Venture Investments, Johnson & Johnson Innovation – JJDC, Inc. (JJDC)

Chris Kaster
Vice President, Business Development, Venture Capital Investing, Boston Scientific

Prof. John Gallacher
Director, Dementia Platform UK,

Hartmuth Kolb, PhD
Head of Neuroscience Biomarkers, Janssen Research & Development


In Cooperation with

Supported by



STC Sanford T. Colb & Co




Astra Zeneca
Johnson & Johnson
Yeda Research and Development
Hogan Lovells


Rodman & Renshaw



Media Partners

MedTech Strategist
Fierce Biotech
IVC Online
  • This field is for validation purposes and should be left unchanged.